NCT04588064 is a NA clinical trial of 68Ga-FAPI PET/CT scan in Lung Adenocarcinoma, sponsored by The First Affiliated Hospital of Xiamen University.

Who is sponsoring NCT04588064?

NCT04588064 is sponsored by The First Affiliated Hospital of Xiamen University.

What drugs are being tested in NCT04588064?

Interventions in NCT04588064: 68Ga-FAPI PET/CT scan.

What condition does NCT04588064 study?

NCT04588064 studies Lung Adenocarcinoma, 18F-FDG, 68Ga-FAPI, PET/CT.

Is NCT04588064 still recruiting?

NCT04588064 is currently completed. Last updated 29 January 2025.

Last reviewed 2025-01-29 · How we verify

NCT04588064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

Completed NA Last updated 29 January 2025

What this trial tests

NA trial testing 68Ga-FAPI PET/CT scan in Lung Adenocarcinoma in 63 participants. Completed in 1 July 2022.

Timeline

1 July 2020

Primary endpoint
1 July 2022

1 July 2022

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	63
Start date	1 July 2020
Primary completion	1 July 2022
Estimated completion	1 July 2022
Sites	1 location across China

Drugs / interventions tested

68Ga-FAPI PET/CT scan

Conditions studied

Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
18F-FDG — all drugs for 18F-FDG →
68Ga-FAPI — all drugs for 68Ga-FAPI →
PET/CT — all drugs for PET/CT →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

Adults 18 to 90, any sex, with Lung Adenocarcinoma or 18F-FDG. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.
Zhang Z, Tao J, Qiu J, Cao Z, et al · · 2024 · cited 21× · PMID 37726505 · DOI 10.1007/s13402-023-00872-z
Novel Tracers and Radionuclides in PET Imaging.
Mason C, Gimblet GR, Lapi SE, Lewis JS. · · 2021 · cited 10× · PMID 34392925 · DOI 10.1016/j.rcl.2021.05.012
18F-FDG and 68Ga-FAPI PET/CT in the Evaluation of Ground-Glass Opacity Nodule.
Chen H, Pang Y, Meng T, Yu X, et al · · 2021 · cited 10× · PMID 33782300 · DOI 10.1097/rlu.0000000000003600
Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT imaging.
Ruan D, Shi S, Guo W, Pang Y, et al · · 2025 · PMID 40411546 · DOI 10.1007/s00259-025-07361-5

Verify or expand the search:

Other trials of 68Ga-FAPI PET/CT scan

Trials testing the same drug.

NCT05574907 — Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01) · NA · unknown

Other recruiting trials for Lung Adenocarcinoma

Currently open trials in the same condition.

NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04588064 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04588064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing